SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

Share Price is delayed by 15 minutes
Get Live Data
54.60    -1.40 (-2.50%)
Bid:
52.60
Ask:
56.60
Spread: 4.00 (7.605%)
Market Cap: £45.60m
FLO Live PriceLast checked at - London Stock Exchange

Intraday Flowtech Fluid. Share Chart

Statement

19 May 2008 13:30

RNS Number : 7780U
Flomerics Group PLC
19 May 2008
 



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATESAUSTRALIACANADA OR JAPAN

FOR IMMEDIATE RELEASE

19th May 2008

FLOMERICS GROUP PLC

Statement re: Posting of Offer Document following Unsolicited Offer

 

 

The Board of Directors of Flomerics Group PLC ("Flomerics" or the "Company") notes the statement by Mentor Graphics, Inc. ("Mentor") that it has posted an offer document to Flomerics shareholders in respect of its unsolicited offer for all the outstanding shares and stock options in Flomerics at a price of 104 pence per share payable in cash (the "Offer"). 

 

The Board of Directors of Flomerics continues to believe the Offer materially undervalues the Company and is actively engaged in assessing other alternatives available to the Company, including potential interest expressed by a number of other parties, which are the subject of ongoing discussions. Shareholders are therefore strongly urged to ignore any documents or announcements that may be made or issued by Mentor or its advisers and not to sell their valuable Flomerics shares.

David Mann, Chairman of Flomerics commented: "We have previously stated that the Offer, which is unsolicited, has been considered by the Board of Flomerics, in conjunction with its independent adviser, and we have unanimously concluded that it does not reflect the true value of Flomerics shares. As such, the Offer does not carry the recommendation of the Flomerics Board of Directors as we do not believe it is in the best interests of Flomerics shareholders." 

The Board of Directors intends to write to its shareholders in due course to explain its current position with regard to the Mentor Offer.

Any discussions with other interested parties continue to be at an early stage and there can be no certainty that an alternative offer will be forthcoming. However, shareholders are strongly recommended to take no action at this stage. A further announcement will be made in due course.

 

Enquiries: 

 

Flomerics Group PLC

Gary Carter

Keith Butcher

Tel: 020 8487 3000

Jefferies International Ltd (Financial adviser to Flomerics)

Andres Pieczanski

Sarah McNicholas

Tel: 020 7029 8000

Oriel Securities Limited (Nominated Adviser and Corporate Broker to Flomerics)

Andrew Edwards

Michael Shaw

Tel: 020 7710 7600

Citigate Dewe Rogerson

Ginny Pulbrook

Seb Hoyle

Tel: 020 7638 9571

 

Jefferies International Limited ("Jefferies International"), which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting for Flomerics and no-one else in connection with the matters referred to herein and will not be responsible to anyone other than Flomerics for providing the protections afforded to clients of Jefferies International or for giving advice in relation to such matters.

Oriel Securities Limited ("Oriel Securities"), which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting for Flomerics and no-one else in connection with the matters referred to herein and will not be responsible to anyone other than Flomerics for providing the protections afforded to clients of Oriel Securities or for giving advice in relation to such matters.

 

 Dealing Disclosure Requirements 

Under the provisions of Rule 8.3 of the Takeover Code (the "Code"), if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Flomerics, all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Nestor, they will be deemed to be a single person for the purpose of Rule 8.3. 

 

Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant securities" of Flomerics by a potential offeror or by Flomerics, or by any of their respective "associates", must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction. 

 

A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel's website at www.thetakeoverpanel.org.uk. 

"Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. 

 

Terms in quotation marks are defined in the Code, which can also be found on the Takeover Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, you should consult the Panel.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPGUUAPAUPRGPB
Date   Source Headline
17th May 20242:54 pmRNSNotice of AGM
9th May 20247:00 amRNSAnnual Financial Report
1st May 20247:00 amRNSHolding(s) in Company
18th Apr 20244:10 pmRNSDirector/PDMR Shareholding
27th Mar 20242:28 pmRNSClarification note regarding Dividend - REPLACE
26th Mar 20247:16 amRNS2023 Annual Unaudited Results
25th Mar 202411:44 amRNSNotice of Results
1st Feb 202410:38 amRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSTrading update
19th Dec 20237:00 amRNSHolding(s) in Company
25th Oct 202311:42 amRNSHolding(s) in Company
31st Aug 20234:25 pmRNSBoard Update
31st Aug 20237:00 amRNSPDMRs - Director Dealings
30th Aug 20237:00 amRNS2023 Half-year report
31st Jul 20237:00 amRNSTrading update & Notice of Half-year results
13th Jun 20231:42 pmRNSResult of AGM
5th Jun 20237:00 amRNSAwards under Long-Term Incentive Plan
5th Jun 20237:00 amRNSBoard update
19th May 20237:00 amRNSAvailability of Documents & Notice of 2023 AGM
15th May 20237:00 amRNSDirector Dealing
26th Apr 20237:01 amRNSAudited Annual Financial Report FY2022
12th Apr 20237:00 amRNSDirectorate Change
12th Apr 20237:00 amRNSUnaudited Preliminary Results-year ended 31.12.22
24th Mar 20237:00 amRNSNotice of Results - revised date
9th Mar 20238:00 amRNSAnnual Results and Presentation via IMC Platform
26th Jan 20237:00 amRNSTrading Update and Notice of Results
11th Jan 20237:00 amRNSBoard changes: NED Appointment & NED Retirement
21st Dec 20224:39 pmRNSHolding(s) in Company
31st Aug 20227:00 amRNSHalf-year Report - six months ended 30 June 2022
8th Aug 20226:27 pmRNSHolding(s) in Company
4th Aug 20227:30 amRNS2022 Half-Year Results - Investor Presentation
1st Aug 20227:00 amRNSGroup Trading Update & Notice of HY1 2022 results
21st Jul 20221:03 pmRNSHolding(s) in Company
1st Jun 20222:23 pmRNSResult of AGM and Total Voting Rights
18th May 20227:00 amRNSDirector/PDMR Shareholding
5th May 20222:20 pmRNS2021 Annual Report & Notice of 2022 AGM
3rd May 20227:00 amRNSGrant of Options under Long-Term Incentive Plan
30th Mar 20221:21 pmRNSDirector/PDMR Shareholding
29th Mar 20227:00 amRNSFY2021 Results & publication of the Annual Report
25th Mar 20225:36 pmRNSHolding(s) in Company
7th Mar 20229:00 amRNSNotice of Results and Investor Presentation
21st Feb 20225:49 pmRNSHolding(s) in Company
26th Jan 20227:01 amRNSTrading Statement
26th Jan 20227:00 amRNSAppointment of Nominated Adviser and Sole Broker
20th Jan 20224:41 pmRNSSecond Price Monitoring Extn
20th Jan 20224:36 pmRNSPrice Monitoring Extension
20th Dec 202112:58 pmRNSHolding(s) in Company
10th Dec 20214:41 pmRNSSecond Price Monitoring Extn
10th Dec 20214:36 pmRNSPrice Monitoring Extension
15th Nov 20217:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.